{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:24:02Z","timestamp":1761751442664,"version":"build-2065373602"},"reference-count":8,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1111\/bju.14364","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T16:04:43Z","timestamp":1527782683000},"page":"825-834","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["NICE Guidance \u2010 Complicated urinary tract infections: ceftolozane\/tazobactam"],"prefix":"10.1111","volume":"121","member":"311","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"e_1_2_2_2_1","unstructured":"European Association of Urology(2015)Guidelines on urological infections[online; accessed 29\u00a0April\u00a02016]"},{"key":"e_1_2_2_3_1","unstructured":"European Medicines Agency(2015)European public assessment report for Zerbaxa. EMEA\/H\/C\/003772\/0000 [online; accessed 29\u00a0April\u00a02016]"},{"key":"e_1_2_2_4_1","unstructured":"FrassettoLA(2015)Acute pyelonephritis. BMJ Best Practice [online; accessed 29\u00a0April 2016]"},{"key":"e_1_2_2_5_1","unstructured":"Merck Sharp and Dohme Limited(2016)Zerbaxa summary of product characteristics[online; accessed 29\u00a0April\u00a02016]"},{"key":"e_1_2_2_6_1","unstructured":"Public Health England(2015a)English surveillance programme antimicrobial utilisation and resistance (ESPAUR) report 2015[online; accessed 29\u00a0April\u00a02016]"},{"key":"e_1_2_2_7_1","unstructured":"Public Health England(2015b)Managing common infections: guidance for primary care[online; accessed 29\u00a0April\u00a02016]"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.14364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.14364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:19:40Z","timestamp":1761751180000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.14364"}},"subtitle":["\u00a9 NICE (2016) Complicated urinary tract infections: ceftolozane\/tazobactam"],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/bju.14364"],"URL":"https:\/\/doi.org\/10.1111\/bju.14364","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"2018-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}